Priority | Normalized priority | Dimensions | Specific dimensions | Base score | Score | Incidence | Normalized score | Final score | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Reusable | Disposable | MAX | (%) | Reusable | Disposable | Reusable | Disposable | ||||
1 | 0.222 | Effectiveness (practical research) | 2 | 2 | 4 | 100 | 0.50 | 0.50 | |||
Total | 4 | 0.50 | 0.50 | 0.11 | 0.11 | ||||||
2 | 0.194 | Process analysis | 2 | 2 | 4 | 36 | 0.18 | 0.18 | |||
Economic and financial impact | CEA | 1 | 2 | 3 | 27 | 0.09 | 0.18 | ||||
BIA | 2 | 2 | 4 | 36 | 0.18 | 0.18 | |||||
Total | 11 | 0.45 | 0.55 | 0.09 | 0.11 | ||||||
3 | 0.167 | Patient safety | 1 | 2 | 3 | 100 | 0.33 | 0.67 | |||
Total | 3 | 0.33 | 0.67 | 0.06 | 0.11 | ||||||
4 | 0.139 | Quantitative | 1 | 2 | 3 | 50 | 0.17 | 0.33 | |||
Organizational impact | Qualitative | 1 | 2 | 3 | 50 | 0.17 | 0.33 | ||||
Total | 6 | 0.33 | 0.67 | 0.05 | 0.09 | ||||||
5 | 0.111 | Scientific papers quality | 1 | 1 | 2 | 10 | 0.05 | 0.05 | |||
Description of the technology | 1 | 2 | 3 | 15 | 0.05 | 0.10 | |||||
Description of the pathology | 2 | 2 | 4 | 20 | 0.10 | 0.10 | |||||
General relevance | Real and potential audience | 2 | 2 | 4 | 20 | 0.10 | 0.10 | ||||
Goals (agreement with company strategy) | 1 | 2 | 3 | 15 | 0.05 | 0.10 | |||||
Potential benefits | 2 | 2 | 4 | 20 | 0.10 | 0.10 | |||||
Total | 20 | 0.45 | 0.55 | 0.05 | 0.06 | ||||||
6 | 0.083 | Legal aspects | 1 | 1 | 2 | 100 | 0.50 | 0.50 | |||
Total | 2 | 0.50 | 0.50 | 0.04 | 0.04 | ||||||
7 | 0.056 | Ethical impact | 1 | 2 | 3 | 50 | 0.17 | 0.33 | |||
Social and ethical impact | Social impact | 2 | 1 | 3 | 50 | 0.33 | 0.17 | ||||
Total | 6 | 0.50 | 0.50 | 0.03 | 0.03 | ||||||
8 | 0.028 | Equity | 2 | 2 | 4 | 100 | 0.50 | 0.50 | |||
Total | 4 | 0.50 | 0.50 | 0.01 | 0.01 | ||||||
FINAL SCORE | 0.43 | 0.57 |